Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 16/20 | 0.69 |
| ▸ | LTB4R | Q15722 | 5/20 | 0.69 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | HTR2B | P41595 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9417960 | 0.96 | NR1H4 (0.63) | NR1H4LTB4RLTB4R2MEN1ALDH1A1 | |
| SCHEMBL8610596 | 0.89 | NR1H4 (0.67) | NR1H4LTB4RLTB4R2MEN1ALDH1A1 | |
| Ly-255283 SCHEMBL7749547 | 0.82 | NR1H4 (1.00) | NR1H4LTB4RLTB4R2MEN1ALDH1A1 | |
| SCHEMBL9417932 | 0.81 | NR1H4 (0.57) | NR1H4LTB4RLTB4R2MEN1ALDH1A1 | |
| SCHEMBL7646400 | 0.81 | LTB4R (0.71) | NR1H4LTB4RLTB4R2 | |
| SCHEMBL10346817 | 0.80 | NR1H4 (0.66) | NR1H4LTB4RLTB4R2MEN1ALDH1A1 | |
| SCHEMBL9417801 | 0.80 | LTB4R (0.56) | NR1H4LTB4RLTB4R2MEN1ALDH1A1 | |
| SCHEMBL7699998 | 0.80 | NR1H4 (0.48) | NR1H4LTB4RLTB4R2MEN1ALDH1A1 | |
| SCHEMBL7646883 | 0.79 | LTB4R (0.73) | NR1H4LTB4RLTB4R2 | |
| Bicarbonate SCHEMBL10346826 | 0.78 | NR1H4 (0.64) | NR1H4LTB4RLTB4R2MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731002-A2 | SYSTEMS FOR PRODUCTION OF PRODUCTS TO PROMOTE NITROGEN USE EFFICIENCY IN PLANTS | Tenfold Technologies, LLC (US) | 2026-04-29 | — | — | EP | claimed |
| WO-2024263793-A2 | SYSTEMS FOR PRODUCTION OF PRODUCTS TO PROMOTE NITROGEN USE EFFICIENCY IN PLANTS | Tenfold Technologies, LLC (US) | 2024-12-26 | — | — | WO | claimed |
| US-20170333516-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR AGE-RELATED MACULAR DEGENERATION | JUNTENDO EDUCATIONAL FOUNDATION (JP) | 2017-11-23 | — | — | US | claimed |
| WO-2001034199-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| US-5563164-A | TREATING ARTHRITIS, PSORIASIS, ASTHMA, INFLAMMATORY BOWEL DISEASE, OR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1996-10-08 | — | — | US | claimed |
| US-5478857-A | Administering inhibitor of phospholipase A2 | ELI LILLY AND COMPANY (US) | 1995-12-26 | — | — | US | claimed |
| US-5294613-A | Benzene derivatives of p-substituted ether and acid or ester | ELI LILLY AND COMPANY (US) | 1994-03-15 | — | — | US | claimed |
| US-4945099-A | LEUKOTRIENE ANTAGONIST | ELI LILLY AND COMPANY (US) | 1990-07-31 | — | — | US | claimed |
| EP-0276065-B1 | ANTI-INFLAMMATORY AGENTS | ELI LILLY AND COMPANY (US) | 1990-06-06 | — | — | EP | claimed |
| EP-0276065-A1 | Anti-inflammatory agents | ELI LILLY AND COMPANY (US) | 1988-07-27 | — | — | EP | claimed |
| EP-4731002-A2 | SYSTEMS FOR PRODUCTION OF PRODUCTS TO PROMOTE NITROGEN USE EFFICIENCY IN PLANTS | Tenfold Technologies, LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024263793-A2 | SYSTEMS FOR PRODUCTION OF PRODUCTS TO PROMOTE NITROGEN USE EFFICIENCY IN PLANTS | Tenfold Technologies, LLC (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| EP-3327001-B1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | UNIV DONGGUK IND ACAD COOP (KR) | 2022-04-13 | — | — | EP | disclosed |
| WO-1995017183-A1 | USE OF PLA2 INHIBITORS AS TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1995-06-29 | — | — | WO | disclosed |
| US-5294613-A | Benzene derivatives of p-substituted ether and acid or ester | ELI LILLY AND COMPANY (US) | 1994-03-15 | — | — | US | disclosed |
| US-5098613-A | Aromatic ethers for treatment of mammals | ELI LILLY AND COMPANY (US) | 1992-03-24 | — | — | US | disclosed |
| US-4945099-A | LEUKOTRIENE ANTAGONIST | ELI LILLY AND COMPANY (US) | 1990-07-31 | — | — | US | disclosed |
| EP-0276065-A1 | Anti-inflammatory agents | ELI LILLY AND COMPANY (US) | 1988-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333516-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR AGE-RELATED MACULAR DEGENERATION | LTB4R, LTA4H, LTB4R2 | NR1H4 1713/4885LTB4R 1/4885LTB4R2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.